| Myriam El Gaaloul, Andre Marie Tchouatieu, Kassoum Kayentao, Brice Campo, Benedicte Buffet, Hanu Ramachandruni, Jean Louis Ndiaye, Timothy N. C. Wells, Celine Audibert, Jane Achan, Cristina Donini, Hellen C. Barsosio, Halidou Tinto Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile Journal Article In: Malaria journal, vol. 23, iss. 1, pp. 315, 2024, ISSN: 1475-2875. @article{nokey,
title = {Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile},
author = {Myriam El Gaaloul and Andre Marie Tchouatieu and Kassoum Kayentao and Brice Campo and Benedicte Buffet and Hanu Ramachandruni and Jean Louis Ndiaye and Timothy N. C. Wells and Celine Audibert and Jane Achan and Cristina Donini and Hellen C. Barsosio and Halidou Tinto},
url = {https://pubmed.ncbi.nlm.nih.gov/39425110/},
doi = {10.1186/S12936-024-05128-1},
issn = {1475-2875},
year = {2024},
date = {2024-01-01},
journal = {Malaria journal},
volume = {23},
issue = {1},
pages = {315},
publisher = {Malar J},
abstract = {\<p\>Malaria is preventable, but the burden of disease remains high with over 249 million cases and 608,000 deaths reported in 2022. Historically, the most important protective interventions have been vector control and chemopreventive medicines with over 50 million children receiving seasonal malaria chemoprevention in the year 2023. Two vaccines are approved and starting to be deployed, bringing additional protection for children up to 36 months. However, the impact of these currently available tools is somewhat limited on various fronts. Vaccines exhibit partial efficacy, are relatively costly, and not accessible in all settings. The challenges encountered with chemoprevention are barriers to acceptability and feasibility, including frequency of dosing, and the lack of options in the first trimester of pregnancy and for women living with HIV. Also, the emergence of resistance against chemopreventive medicines is concerning. To address these limitations, a target product profile (TPP) is proposed as a road map to guide innovation and to boost the quest for novel chemopreventive alternatives. This TPP describes the ideal product attributes, while acknowledging potential trade-offs that may be needed. Critically, it considers the target populations most at risk; primarily infants, children, and pregnant women. Malaria control and elimination requires appropriate chemoprevention, not only in areas of high endemicity and transmission, but also in lower transmission areas where immunity is declining, as well as for travellers from areas where malaria has been eliminated. New medicines should show acceptable safety and tolerability, with high and long protective efficacy. Formulations and costs need to support operational adherence, access, and effectiveness. Next generation long-acting oral and injectable drugs are likely to constitute the backbone of malaria prevention. Therefore, the perspectives of front-line experts in malaria prevention, researchers, and those involved in drug development are captured in the TPP. This inclusive approach aims at concentrating efforts and aligning responses across the community to develop new and transformative medicines.\</p\>},
keywords = {Administration, Andre Marie Tchouatieu, Antimalarials* / administration \& dosage, Antimalarials* / therapeutic use, Chemoprevention* / methods, doi:10.1186/s12936-024-05128-1, Female, Halidou Tinto, Humans, Injections, Malaria* / prevention \& control, MEDLINE, Myriam El Gaaloul, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, Oral, PMC11490162, pmid:39425110, Pregnancy, PubMed Abstract, Review},
pubstate = {published},
tppubtype = {article}
}
<p>Malaria is preventable, but the burden of disease remains high with over 249 million cases and 608,000 deaths reported in 2022. Historically, the most important protective interventions have been vector control and chemopreventive medicines with over 50 million children receiving seasonal malaria chemoprevention in the year 2023. Two vaccines are approved and starting to be deployed, bringing additional protection for children up to 36 months. However, the impact of these currently available tools is somewhat limited on various fronts. Vaccines exhibit partial efficacy, are relatively costly, and not accessible in all settings. The challenges encountered with chemoprevention are barriers to acceptability and feasibility, including frequency of dosing, and the lack of options in the first trimester of pregnancy and for women living with HIV. Also, the emergence of resistance against chemopreventive medicines is concerning. To address these limitations, a target product profile (TPP) is proposed as a road map to guide innovation and to boost the quest for novel chemopreventive alternatives. This TPP describes the ideal product attributes, while acknowledging potential trade-offs that may be needed. Critically, it considers the target populations most at risk; primarily infants, children, and pregnant women. Malaria control and elimination requires appropriate chemoprevention, not only in areas of high endemicity and transmission, but also in lower transmission areas where immunity is declining, as well as for travellers from areas where malaria has been eliminated. New medicines should show acceptable safety and tolerability, with high and long protective efficacy. Formulations and costs need to support operational adherence, access, and effectiveness. Next generation long-acting oral and injectable drugs are likely to constitute the backbone of malaria prevention. Therefore, the perspectives of front-line experts in malaria prevention, researchers, and those involved in drug development are captured in the TPP. This inclusive approach aims at concentrating efforts and aligning responses across the community to develop new and transformative medicines.</p> |
